Intuitive Surgical Sees $10.78 Billion Trading Volume Despite 28.74% Decline

On July 14, 2025, Intuitive Surgical (ISRG) saw a trading volume of $10.78 billion, marking a 28.74% decrease from the previous day. The company's stock price rose by 0.86%, marking the third consecutive day of gains, despite a 1.83% decline over the past three days.

Intuitive Surgical has received FDA approval for its new Vessel Sealer Curved, an advanced bipolar electrosurgical instrument designed to seal, cut, grasp, and dissect tissue. This new tool is fully wristed and compatible with the company's multiport da Vinci surgical systems, enhancing its capabilities in minimally invasive surgery.

Despite the positive news, there are concerns about the potential impact of hospital capital expenditure (capex) headwinds on Intuitive Surgical's performance. Analysts are debating whether this is a temporary setback or a lasting risk for the company. The FDA's clearance of the Vessel Sealer Curved is seen as a significant development, potentially opening up new opportunities for the company in the surgical robotics market.

Intuitive Surgical's stock has been the subject of various analyst ratings and price target adjustments. Piper Sandler recently reaffirmed their buy rating on the company, while Leerink Partners adjusted their price target following the FDA approval of the Vessel Sealer Curved. These developments reflect the market's confidence in Intuitive Surgical's innovative products and its leadership position in the surgical robotics industry.